Skip to main content
Erschienen in: Clinical Rheumatology 1/2010

01.01.2010 | Case Report

Successful treatment of hypertrophic pachymeningitis in refractory Wegener’s granulomatosis with rituximab

verfasst von: Aman Sharma, Susheel Kumar, Ajay Wanchu, Vivek Lal, Ramandeep Singh, Vishali Gupta, Surjit Singh, Amod Gupta

Erschienen in: Clinical Rheumatology | Ausgabe 1/2010

Einloggen, um Zugang zu erhalten

Abstract

Central nervous involvement (CNS) is uncommon manifestation of Wegener’s granulomatosis (WG). We are describing a patient with refractory WG with CNS involvement which responded to rituximab. This lady presented with nodular scleritis. Three months later, she developed headache, vision loss with complete opthalmoplegia, and relative afferent papillary defect. The brain MRI showed thickened dura along ant temporal region and enlargement of right cavernous sinus. C ANCA and PR 3 ELISA were positive. Non-contrast CT scan of orbit and paranasal sinuses showed soft tissue swelling of the right orbit along with mucosal thickening of right maxillary sinus. There were bilateral upper lobe nodules on HRCT of the chest. She responded to 3 days of methylprednisolone pulses and 1 g pulse cyclophosphamide but had multiple relapses while receiving high dose oral steroids and pulse cyclophosphamide. Then she was given four infusions of rituximab (375 mg/m2) at one-weekly interval. She had complete remission following rituximab. She relapsed after 6 months but again responded to repeat rituximab infusion.
Literatur
1.
Zurück zum Zitat Nishino H, Rubino FA, DeRemee RA, Swanson JW, Parisi JE (1993) Neurological involvement in Wegener’s granulomatosis: an analysis of 324 consecutive patients at the Mayo Clinic. Ann Neurol 33:4–9CrossRefPubMed Nishino H, Rubino FA, DeRemee RA, Swanson JW, Parisi JE (1993) Neurological involvement in Wegener’s granulomatosis: an analysis of 324 consecutive patients at the Mayo Clinic. Ann Neurol 33:4–9CrossRefPubMed
2.
Zurück zum Zitat Fauci A, Haynes B, Katz P, Wolff S (1983) Wegener’s granulomatosis: prospective clinical and therapeutic experience with 85 patients for 21 years. Ann Intern Med 98:76–85PubMed Fauci A, Haynes B, Katz P, Wolff S (1983) Wegener’s granulomatosis: prospective clinical and therapeutic experience with 85 patients for 21 years. Ann Intern Med 98:76–85PubMed
3.
Zurück zum Zitat Hoffman G, Kerr G, Leavitt R et al (1992) Wegener’s granulomatosis: an analysis of 158 patients. Ann Intern Med 116:488–499PubMed Hoffman G, Kerr G, Leavitt R et al (1992) Wegener’s granulomatosis: an analysis of 158 patients. Ann Intern Med 116:488–499PubMed
4.
Zurück zum Zitat Guillevin L, Cordier J, Lhote F et al (1997) A prospective, multicenter, randomized trial comparing steroids and pulse cyclophosphamide versus steroids and oral cyclophosphamide in the treatment of generalized Wegener’s granulomatosis. Arthritis Rheum 40:2187–2198CrossRefPubMed Guillevin L, Cordier J, Lhote F et al (1997) A prospective, multicenter, randomized trial comparing steroids and pulse cyclophosphamide versus steroids and oral cyclophosphamide in the treatment of generalized Wegener’s granulomatosis. Arthritis Rheum 40:2187–2198CrossRefPubMed
5.
Zurück zum Zitat de Groot K, Jayne D, Tesar V, Savage C (2005) Randomised controlled trial of daily oral versus pulse cyclophosphamide for induction of remission in ANCA-associated systemic vasculitis [abstract]. Kidney Blood Press Res 28:195 de Groot K, Jayne D, Tesar V, Savage C (2005) Randomised controlled trial of daily oral versus pulse cyclophosphamide for induction of remission in ANCA-associated systemic vasculitis [abstract]. Kidney Blood Press Res 28:195
6.
Zurück zum Zitat de Groot K, Adu D, Savage C (2001) The value of pulse cyclophosphamide in ANCA-associated vasculitis: meta-analysis and critical review. Nephrol Dial Transplant 16:2018–2027CrossRefPubMed de Groot K, Adu D, Savage C (2001) The value of pulse cyclophosphamide in ANCA-associated vasculitis: meta-analysis and critical review. Nephrol Dial Transplant 16:2018–2027CrossRefPubMed
7.
Zurück zum Zitat Keogh K, Wylam M, Stone J, Specks U (2005) Induction of remission by B lymphocyte depletion in eleven patients with refractory antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum 52:262–268CrossRefPubMed Keogh K, Wylam M, Stone J, Specks U (2005) Induction of remission by B lymphocyte depletion in eleven patients with refractory antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum 52:262–268CrossRefPubMed
8.
Zurück zum Zitat Eriksson P (2005) Nine patients with anti-neutrophil cytoplasmic antibody-positive vasculitis successfully treated with rituximab. J Intern Med 257:540–548CrossRefPubMed Eriksson P (2005) Nine patients with anti-neutrophil cytoplasmic antibody-positive vasculitis successfully treated with rituximab. J Intern Med 257:540–548CrossRefPubMed
9.
Zurück zum Zitat Aries PM, Hellmich B, Voswinkel J, Both M, Nölle B, Holl-Ulrich K, Lamprecht P, Gross WL (2006) Lack of efficacy of rituximab in Wegener’s granulomatosis with refractory granulomatous manifestations. Ann Rheum Dis 65:853–858CrossRefPubMed Aries PM, Hellmich B, Voswinkel J, Both M, Nölle B, Holl-Ulrich K, Lamprecht P, Gross WL (2006) Lack of efficacy of rituximab in Wegener’s granulomatosis with refractory granulomatous manifestations. Ann Rheum Dis 65:853–858CrossRefPubMed
10.
Zurück zum Zitat Chung SA, Seo P (2009) Advances in the use of biologic agents for the treatment of systemic vasculitis. Curr Opin Rheumatol 21:3–9CrossRefPubMed Chung SA, Seo P (2009) Advances in the use of biologic agents for the treatment of systemic vasculitis. Curr Opin Rheumatol 21:3–9CrossRefPubMed
Metadaten
Titel
Successful treatment of hypertrophic pachymeningitis in refractory Wegener’s granulomatosis with rituximab
verfasst von
Aman Sharma
Susheel Kumar
Ajay Wanchu
Vivek Lal
Ramandeep Singh
Vishali Gupta
Surjit Singh
Amod Gupta
Publikationsdatum
01.01.2010
Verlag
Springer-Verlag
Erschienen in
Clinical Rheumatology / Ausgabe 1/2010
Print ISSN: 0770-3198
Elektronische ISSN: 1434-9949
DOI
https://doi.org/10.1007/s10067-009-1291-z

Weitere Artikel der Ausgabe 1/2010

Clinical Rheumatology 1/2010 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.